Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2026 May 10.
Published in final edited form as: Nat Rev Neurol. 2025 Aug 14;21(10):529–543. doi: 10.1038/s41582-025-01128-0

Spreading depolarization as a therapeutic target in migraine

Andrea M Harriott 1,✉, Cenk Ayata 1
PMCID: PMC13157258  NIHMSID: NIHMS2168056  PMID: 40813918

Abstract

Migraine with aura is characterized by recurrent attacks of visual and, occasionally, sensory, language and/or motor disturbances, typically followed by headache. Migraine with aura can be associated with allodynia and vascular and psychiatric comorbidities. The electrophysiological cause of the aura is cortical spreading depolarization, a wave of depolarization that propagates slowly across the cortical surface, producing reversible metabolic and electrochemical perturbations. In this Review, we focus on the relationship of spreading depolarization with migraine aura and migraine headache. Abundant evidence causally links spreading depolarization to the headache phase of migraine with aura, as it can activate trigeminal nociceptors, produce dural and cortical inflammation, and induce trigeminal pain behaviour in rodents. In experimental models, migraine prophylaxis reduces susceptibility to spreading depolarization, and abortive treatments abrogate trigeminal pain behaviour that is induced by spreading depolarization. Although questions remain about the role of spreading depolarization in migraine with aura and models of spreading depolarization need to be refined, the cumulative evidence suggests that spreading depolarization is a putative target for therapeutic intervention in migraine. Elucidating the mechanisms by which spreading depolarization can induce trigeminal pain could facilitate drug discovery, and models of spreading depolarization could be effective screening platforms for migraine therapies.

Introduction

More than 1 billion people worldwide experience migraine annually, and it accounts for an estimated 45.1 million years lost owing to migraine-related disability1-5. In the United States, migraine affects 12% of the general population and is three times more common in women than in men6. Migraine attacks are often characterized by recurrent bouts of severe headache, sensitivity to light and sound, nausea and vomiting7, and attacks can be precipitated by stress, sleep disruption and/or hormone fluctuations8. Though phenotypes vary, attacks are broadly classified as migraine without aura or migraine with aura; the latter is characterized by episodes of transient neurological disturbance — usually visual, but also sensory, language and/or motor — that precede the headache9. These neurological disturbances are widely thought to result from spreading depolarization (also called spreading depression), an intense wave of pan-depolarization that slowly propagates through the grey matter, temporarily negating the ion gradients across membranes in most, if not all, cells in its path, thereby silencing all electrical activity in its wake for several minutes.

Spreading depolarization was first described by Aristides Leao in 194410 and has since been associated with multiple neurological conditions, including ischaemic stroke, intracranial haemorrhage, brain trauma and seizures. However, spreading depolarization is most prominently associated with migraine aura. As early as the 1940s, the clinical signs and symptoms of migraine aura were suspected to result from transient disturbance in cortical neuronal activity that propagated through brain tissue at a rate of millimetres per minute11,12. Today, extensive evidence indicates that spreading depolarization is responsible for migraine aura10,13 and that it also activates trigeminal nociceptors14-17 and induces trigeminal cutaneous allodynia, suggesting that spreading depolarization is a trigger for migraine headache18-20.

Spreading depolarization is phylogenetically conserved and has been observed in the CNS in a wide range of species, from locusts and tropical butterflies to lissencephalic and gyrencephalic mammals21-23. In the human brain, spreading depolarization has been recorded in vitro in temporal, frontal and occipital lobe slices after surgical resection for the treatment of refractory epilepsy24, and in vivo via subdural electrocorticographic recordings in people with brain injury25 or undergoing pre-surgical planning26. Despite the evolutionary conservation of spreading depolarization, whether it affords any survival advantage is unclear.

In this Review, we consider the relationship of spreading depolarization to migraine with aura. We first consider the nature and characteristics of migraine with aura, before reviewing the evidence that spreading depolarization is the cause of aura symptoms. We then also discuss the evidence that spreading depolarization can be the trigger for migraine headache and the possible mechanisms for this process. Finally, we highlight the potential of spreading depolarization as a putative target for therapeutic intervention in migraine and as a model for screening in therapeutic development.

Migraine aura

Migraine with aura is a distinct subtype of migraine that affects an estimated 30% of people with migraine27 — a given individual can experience attacks with or without aura. Similar to migraine without aura, migraine with aura is more common in women28. Migraine with aura is associated with high rates of allodynia and vascular and psychiatric comorbidities9,29-32; in a large study of nearly 50,000 people, migraine with aura was associated with higher rates of anxiety and depression33, photophobia and severe cutaneous allodynia than migraine without aura9,29-32,34. Cutaneous allodynia, which occurs in 60–70% of people with migraine during or between attacks, is predictive of treatment resistance35, disability and progression to chronic migraine29, indicating that these outcomes are more likely in people with migraine with aura.

The most common symptom of migraine aura is visual disturbance, which occurs in 98–99% of people who experience migraine with aura36,37; these disturbances are described as elementary (as opposed to well-formed), including wavy, zigzag or jagged-edged lines that often take the shape of a crescent and resembling the bastions of a fort36,38,39, and start near the central vision and slowly spread centrifugally into the right or left visual field (Fig. 1). A perceptible scotoma (loss of vision) can develop in the wake of the propagating positive symptom and recovers over several minutes. Less commonly (2.6–8%), people describe scintillations and flickering or flashing lights that move across the visual field, small black dots, visual distortions such as “looking through heat waves or water”, visual hallucinations, blurring, photopsia, halos, oscillopsia, micropsia, teleopsia, macropsia or pelopsia36,38,40. For 60–70% of people, symptoms are stereotypical across attacks36. Non-visual symptoms occur in a subset of people, often after the onset of visual symptoms38. Non-visual symptoms include sensory disturbances (31–36%), dysphagia (10%), and sensory or motor symptoms (6%)36,37. Sensory and motor symptoms are often peri-oral or in the upper extremities, with a gradual progression that starts in the hand and progressively affects the arm37.

Fig. 1 ∣. Mechanisms of migraine with aura initiation.

Fig. 1 ∣

a, Migraine aura is most often described as a transient visual disturbance that appears as crescent-shaped zigzag lines that affect a visual hemifield. b, Spreading depolarization slowly propagates in grey matter (1) and is associated with K+ efflux, uncontrolled release of neurotransmitters and neuromodulators, tissue acidosis and cytokine release. This process leads to activation of meningeal nociceptors (2), which activate trigeminothalamic pathways (3) that ultimately project to the somatosensory cortex (4), leading to perception of pain (5). The contribution of hypothalamic activation before and during the headache phase is the focus of ongoing work.

Disturbances that affect visual, somatosensory, motor or language function are conspicuous and therefore easy to perceive, but migraine aura can cause other disturbances, such as olfactory hallucinations, depersonalization, derealization and mental fog41. In one study, people described aura symptoms that included strange smells, dream-like states, disorientation, and strange or metallic tastes42. Olfactory hallucinations (phantosmia) have also been described in case series and reports; for example, 81% of a paediatric cohort experienced olfactory disturbances that lasted 15–50 min before the onset of headache43. Phantom odours were mainly spontaneous rather than triggered exogenously, and included vinegar, burned plastic, cigarette smoke and petrol. These symptoms could theoretically be manifestations of spreading depolarization in brain regions that are involved in producing hallucinations, such as the mesial temporal lobe44.

Familial hemiplegic migraine types 1–3 (ref. 45) (and possibly 4 (refs. 45,46)) are rare autosomal dominant forms of migraine with aura that have additional symptoms. The distinguishing feature of these attacks is hemiparesis or hemiplegia alongside other aura symptoms. However, presentations vary47 and can include severe manifestations such as encephalopathy, coma, cerebral oedema, seizure and ataxia48-50.

Mechanisms of spreading depolarization

The mechanisms that underlie the initiation and propagation of spreading depolarization are complex and incompletely understood; as they have been reviewed in detail elsewhere51-55, we provide a simplified overview (Fig. 1). Spreading depolarization is an intense neuroglial depolarization that silences all electrical activity in a given brain region. When a sufficiently intense stimulus causes simultaneous depolarization in a critical volume of brain tissue (~1 mm3 in the rodent brain), neurons within that tissue undergo a precipitous drop in membrane resistance54. Transmembrane ion flux diminishes the electrochemical gradient so that membrane potentials approach zero in tens of thousands of neurons and, presumably, all other cells in the region54. Immense K+ efflux elevates extracellular K+ concentration and intracellular Ca2+ concentration54,56 and triggers astrocytic Ca2+ waves57. Conversely, Na+, Cl− and water influx results in swelling, most prominently in the dendritic neuropil56. Transmembrane ion fluxes also trigger release of virtually all neurotransmitter and neuromodulator molecules (for example, glutamate, glycine and adenosine) from neurons and glia independent of action potentials, which have myriad downstream effects58-60.

The near-complete depolarization of neuronal membranes precludes action potentials and synaptic transmission, and the affected brain tissue becomes electrophysiologically silent, though brief neuronal burst firing can occur at the outset of the depolarization54. Even after repolarization, synaptic silence continues because of the substances released during spreading depolarization, such as adenosine, which activates A1 receptors and reduces the probability of presynaptic neurotransmitter release59. Whereas action potentials and postsynaptic potentials are silenced, the transmembrane ion and water shifts create a slow but high-amplitude (up to ~30 mV) negative potential shift (known as the direct current (DC) shift) in the extracellular space. This shift is the electrophysiological signature of spreading depolarization and can be easily detected by use of intraparenchymal, pial or dural electrodes; signal attenuation and spatial averaging make detection of spreading depolarization with extracranial electrodes challenging.

Extracellular K+ and glutamate, which are both strong depolarizing agents, diffuse towards and depolarize nearby neurons, thereby precipitating the same cycle of membrane transformation and K+ and glutamate efflux61-64. Though the rise in extracellular K+ is the critical element, glutamate fuels the wave propagation via activation of N-methyl-d-aspartate (NMDA) receptors65-68. In this way, the spreading depolarization wave propagates into contiguous tissue at a speed of a few millimetres per minute without the need for action potentials.

In the lissencephalic rodent cortex, spreading depolarization propagates radially from the point of initiation, whereas in the gyrencephalic porcine cortex, and presumably also in the human cortex, the pattern is more complex, with spiral or colliding waves and re-entrant or reverberating patterns69,70 (Fig. 2). Spreading depolarization can also develop in or propagate into subcortical structures with high neuronal density, including the striatum71, and can re-enter the cortex72, particularly in brains with high susceptibility (for example, in familial hemiplegic migraine). Thalamic spreading depolarization can produce bilateral visual and somatosensory cortical dysfunction and symptoms73.

Fig. 2 ∣. Propagation patterns of spreading depolarization in lissencephalic and gyrencephalic cortices.

Fig. 2 ∣

a, In the lissencephalic cortex, spreading depolarization propagates radially or centrifugally from the point of initiation. b, In the gyrencephalic cortex, spreading depolarization patterns are more complex and can take the form of centrifugal, spiral, colliding or reverberating waves. These patterns can affect downstream events and symptomatology69.

In the healthy brain, all transmembrane ion and water perturbations during spreading depression recover within 1 min via cellular re-uptake and vascular clearance54. However, spreading depolarization imposes a tremendous metabolic burden (for example, oxygen and glucose consumption, glycogen breakdown and acidosis) and large but species-dependent perturbations of cerebral perfusion54. In mice, early hypoperfusion develops with the DC shift74-77. As the tissue starts to repolarize, cerebral blood flow transiently normalizes but then gives way to oligaemia (~50% of baseline) that is characteristic of spreading depolarization. In the rat, the initial hypoperfusion is much less conspicuous, and the predominant cerebral blood flow response is a large hyperaemia that develops some time after the DC shift and peaks after complete repolarization before evolving into a smaller oligaemia (~20% of baseline)54,75. The cerebral blood flow response in the human brain is not clear owing to a lack of concurrent high-resolution electrophysiological and cerebral blood flow measurements. Other vascular effects of spreading depolarization include blood–brain barrier (BBB) disruption that starts a few hours after spreading depolarization and lasts for up to 24 h in mice78. Similar BBB opening has been documented after an attack of familial hemiplegic migraine79-81. Attempts to detect the same in migraine with or without aura by use of dynamic contrast-enhanced MRI have been unrevealing82,83, possibly owing to milder BBB disruption or methodological limitations such as insufficient sensitivity, caveats in study design and low statistical power. Spreading depolarization also produces a transient obliteration of the perivascular space, which can be detected with two-photon imaging through thinned skull in mice and could affect the timing and detection of changes in BBB integrity84. Spreading depolarization also induces ultrastructural and gene expression changes in virtually all cells in brain tissue, including neurons, astrocytes, microglia and endothelial cells, and in the trigeminal ganglion, including neurons and fibroblasts56,78,85-90. The electrophysiological, haemodynamic, metabolic, ultrastructural and gene expression changes that occur with spreading depolarization cause no detectable injury in an otherwise healthy brain91-93.

It is important to keep in mind the limitations of the preclinical studies on which much of our understanding of spreading depolarization is based. The use of different methods to induce spreading depolarization (application of high-concentration KCl to the cortical surface, electrical stimulation and pinprick injury) and detect it (laser Doppler flow or electrical recordings) have led to variation in the reported properties of spreading depolarization, the apparent mechanisms of initiation and propagation, and the pharmacological susceptibility of spreading depolarization to various drugs94,95. In addition, many preclinical studies (though not all) involve paradigms in which multiple waves of spreading depolarization are induced. As migraine with aura is likely to involve a single wave, the clinical relevance of these paradigms remains unclear. However, in most cases, a single spreading depolarization wave had the same downstream effects as multiple waves but with a smaller response magnitude18-20,78,84,96,97.

Spreading depolarization as the cause of migraine aura

Multiple lines of evidence indicate that spreading depolarization is the cause of migraine aura; this evidence is discussed below. Though these observations individually do not directly prove a causal relationship, the combination of clinical observations, changes in cerebral blood flow and changes in brain activity that coincide with spreading depolarization provides strong support to the hypothesis that spreading depression underlies migraine aura.

Congruence with features of aura

As early as 1870, Hubert Airy first postulated that the visual disturbance experienced during migraine with aura was related to a “temporary suspension of function” of nerve cells that “propagated by contiguity”39. What we now know about the mechanisms of spreading depolarization supports Airy’s hypothesis. The initial increase in neuronal activity readily explains the initial positive aura symptoms, such as scintillations or zigzag lines in the vision, and the subsequent reversible neuronal silencing can explain the negative symptoms, such as scotoma, that follow. Not every aura involves positive symptoms followed by negative symptoms, and according to the ICHD-3, either alone is diagnostically valid7. Furthermore, resolution of symptoms progresses in the same pattern as symptom emergence and corresponds with the pattern of restoration of neuronal activity11,98. Similarly, the typical pattern in which sensory symptoms spread — from the hand up the arm and into the face and tongue — is consistent with spreading of depolarization across the somatosensory homunculus39. In summary, spreading depolarization is the only pathophysiological process that has been described so far that can explain all the salient features of migraine aura37.

Congruence with cerebral haemodynamic changes

Despite methodological limitations, several studies have identified spreading oligaemia as a possible footprint of a preceding spreading depolarization event in migraine with aura99-102. Spreading hyperaemia is followed by persistent spreading hypoperfusion or oligaemia that can be detected in humans and presents with a concomitant increase in cerebral metabolic rate of oxygen consumption103. The use of xenon-133 to monitor cerebral blood flow in people with migraine has revealed an initial focal hyperaemia when a migraine attack begins, followed by reductions in regional cerebral blood that start in the posterior cerebral cortex and spread anteriorly at a rate of approximately 2 mm/min, concordant with the speed at which spreading depolarization propagates99.

During provoked migraine attacks, appropriate functional hyperaemia was observed in normal brain tissue upon task-induced neural activity, even when oligaemia persisted in regions with reduced blood flow100-102. The spread of oligaemia does not respect vascular territories, suggesting that a vasospasm-related event is not the cause of the oligaemia99. Notably, oligaemia affects the auditory cortex, posterior parietal cortex and hand supplemental motor cortex, suggesting that spreading depolarization can propagate beyond the primary visual cortex99. This spread could explain the non-visual symptoms of migraine aura, although haemodynamic disturbances in these brain regions did not always temporally correlate with symptoms. In some instances, oligaemia was observed in brain regions with no corresponding symptom, raising the possibility of silent spreading depolarizations or long-range effects of spreading depolarization100,101.

Congruence with fMRI signals

Functional MRI (fMRI) in spontaneous and triggered attacks of migraine with aura in three individuals demonstrated that the blood oxygenation level-dependent (BOLD) signal increased then decreased, starting in extrastriate visual cortex and spreading anteriorly at the same time as the visual perception of aura, and involved cortical areas that were congruent with the retinotopic organization of visual cortex13. Similarly, the decrease in BOLD signal that followed corresponded to the negative symptoms experienced. The BOLD signal also propagated at a rate that is consistent with a spreading depolarization event. These data provide further supporting evidence that spreading depolarization is the electrophysiological event responsible for migraine aura.

Congruence with changes in electrical brain activity

The detection of changes in electrical activity due to spreading depolarization is almost impossible with surface EEG, but magnetoencephalography (MEG) can be used to measure changes in brain activity in migraine with aura104. In a study of people in whom migraine attacks are triggered by vigorous exercise, MEG recordings revealed large-amplitude (0.8–13 picotesla) biphasic waveforms, slow field activity and decreased cortical activity105. In the gyrencephalic porcine brain, the same MEG signal complexes were linked to an underlying spreading depolarization recorded with electrocorticography106,107. These recordings also showed that the propagation speed and directionality of the signal changed when spreading depolarization propagated into a sulcus106,107. An attack of migraine with aura has been captured during stereotaxic EEG for pre-surgical planning in an individual with comorbid epilepsy26, and the recordings showed that aura was accompanied by a spreading depolarization event that started in the occipital cortex and spread anteriorly26. Taken together, changes in electrical brain activity provide additional support that spreading depolarization explain the symptoms of migraine aura.

Spreading depolarization as a cause of migraine headache

No single event is likely to be the only trigger of migraine headache108, and the available evidence suggests that multiple brain regions are responsible for pain sensation and emotional responses to pain109-111 during different stages of migraine. With respect to spreading depolarization, the fact that aura can occur without a subsequent headache37 makes it clear that this phenomenon cannot be the sole trigger of migraine headache. Nevertheless, several lines of evidence indicate that spreading depolarization can be a causal factor in the pain phase of migraine, as discussed below.

Temporal and spatial correlation with headache

Migraine with aura can be diagnosed without headache (acephalgic migraine aura)7, but headache is present in ~90% of people who present to a headache clinic for migraine with aura36,37 and multiple studies have shown that headache follows or accompanies the onset of aura in a large majority of instances. In a cross-sectional study that included 163 people with migraine with aura, headache started after aura onset in 92.7% of attacks, coincided with aura onset in 4.7% and preceded aura onset in just 2.7% (ref. 37). In a study of 227 people from a Danish tertiary outpatient clinic who were diagnosed with migraine aura, 96% of people with migraine with aura experienced headache associated with the aura, and the aura was accompanied or followed by headache within 60 min in 93% (ref. 112). As part of a multicentre prospective clinical trial, 201 people with migraine with aura recorded aura characteristics in headache diaries113, and these diaries showed that 61% experienced a headache within 15 min of aura symptom onset, 89% within the first 30 min and 90% within 90 min (ref. 113). In a large study that included 980 people with migraine with aura and 128 people with hemiplegic migraine, >90% of those who experienced visual aura had headaches after the aura with a symptom-free interval before the onset of the headache attack114. This temporal association strongly, albeit indirectly, suggests that the spreading depolarization event that underlies aura can trigger downstream events that lead to headache.

Notably, in some people with migraine with aura, the progression of aura symptoms is incongruous with the contiguous centrifugal spread of spreading depolarization; for example, visual and sensory symptoms occur in close temporal succession or even simultaneously108. However, spreading depolarization propagation patterns can be complex in gyrencephalic cortices and are determined by the site of origin, the regional cytoarchitecture (for example, the neuronal and glial density and the myelin content) and venous structures70. Reverberating, colliding and re-entrant waves, and waves that break away from the initial focus could produce a more convoluted evolution of spreading depolarization than the uniform radial propagation seen in lissencephalic brains (Fig. 2). The implications of this variance for downstream trigeminal nociceptive activation and aura symptom progression remain unclear70. Moreover, although spreading depolarization is most simply conceptualized as being a unilateral process that triggers ipsilateral trigeminal nociception and headache accompanied by contralateral neurological symptoms, headaches can be ipsilateral to the neurological symptoms or bilateral, suggesting that our current assumptions about spreading depolarization do not explain the complexity of headache patterns that people with migraine describe. Visual disturbances and perturbations of cortical fMRI signals that coincide with aura can be bilateral115, although the pattern of headache that accompanies these bilateral signs is unclear. These unusual headache locations relative to the aura, which are observed in only a small subset of people, are a gap in our understanding of spreading depolarization as a headache trigger108.

Activation of trigeminocervical nociceptive neurons

Spreading depolarization triggered by KCl or pinprick injury of the cortex in rats produces various patterns of activation and spontaneous firing in meningeal nociceptors, including immediate sustained activation, delayed onset (by 14–25 min) sustained activation and immediate burst activity followed by delayed sustained activation17. Second-order neurons in the trigeminal nucleus caudalis (TNC), which integrates nociceptive afferent inputs, respond within 30–120 min (ref. 17). Spreading depolarization also increases levels of molecular markers of neuronal activation in superficial layers of the TNC, and this effect is attenuated by meningeal nerve transection in rats, suggesting that primary afferents mediate activation of central nociceptors after spreading depolarization14. Activation of nociceptive primary afferents and their second-order neurons are thought to be critical initial steps in migraine pain generation14-17. The different patterns of nociceptor activation could explain the different timing of headache onset in relation to aura — immediate activation of meningeal nociceptors upon spreading depolarization could explain the rare instances in which headache occurs together with aura116, whereas delayed activation could explain the delay between aura and headache onset. In rats, increases in TNC firing following spreading depolarization were not prevented or reversed by administration of lignocaine to the trigeminal ganglion117, suggesting that the TNC firing is driven by central mechanisms rather than primary afferents; however, primary afferent activity was only partially blocked, so further studies are needed to interrogate this finding118. In rats, spreading depolarization increased the rate of TNC neuronal firing in response to innocuous mechanical stimulation (brush and pressure) in the periorbital region; although these changes occurred in both sexes, an additional increase in neuronal response to cutaneous pinch was observed in females16. These data suggest that allodynia induced by spreading depolarization is mediated by central sensitization induced by trigeminal nociceptors.

Besides directly activating trigeminal nociceptive pathways, spreading depolarization also leads to pronounced increases in the mechanosensitivity of meningeal afferents, which could explain pain associated with bending over or head movements in migraine119. Increased spontaneous activity of TNC neurons is likely to be a substrate for headache, and TNC sensitization to non-nociceptive inputs is likely to be a substrate for cutaneous allodynia16. Furthermore, spreading depolarization increases neuronal cutaneous receptive fields from the periorbital region to an area that includes the nasal bridge, ear and maxilla, which could explain the spread of cutaneous allodynia during migraine16.

Increase in trigeminal pain behaviour

Experimental evidence shows that spreading depolarization produces trigeminal pain behaviour that is clinically relevant to the pain phenotypes of migraine. For example, spreading depolarization induced by dural or cortical application of KCl lowers periorbital thermal and mechanical pain thresholds in rodents18,19,97,120, similar to thermal and mechanical allodynia that are commonly reported by people with migraine31,121. Similarly, minimally invasive optogenetic activation of channelrhodopsin-2 to induce spreading depolarization through the intact skull demonstrated that a single spreading depolarization event can produce periorbital mechanical allodynia within 1 h (ref. 20). When optogenetic spreading depolarization was induced every other day for 2 weeks, the pain behaviour was more severe, lasted for at least 4 days and was accompanied by grimace behaviour, a measure of spontaneous discomfort and activation of insular cortical neural circuits involved in pain20,122. Notably, minimally invasive optogenetic spreading depolarization did not cause hind-paw allodynia, suggesting that this behaviour is restricted to the trigeminal region20. These data suggest that spreading depolarization can dose-dependently trigger migraine-relevant pain behaviour.

Migraine drugs reduce activation of nociceptors by spreading depolarization

A variety of evidence indicates that activation of trigeminal nociceptors as a result of spreading depolarization can be reversed by migraine-specific medications. The selective acute migraine drug sumatriptan, a 5-HT1B/1D receptor agonist, nullifies activation of TNC neurons mediated by spreading depolarization induced by cortical KCl microinjection in rats14. The small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist atogepant produced immediate but brief inhibition of the activation of unmyelinated nociceptors induced by spreading depolarization and delayed inhibition of the activation of myelinated nociceptors induced by spreading depolarization123. Atogepant also blocked sensitization of brainstem neurons induced by spreading depolarization124.

The longer-acting CGRP monoclonal antibody fremanezumab blocked spreading depolarization-induced increases in activity of thinly myelinated Aδ fibres and blocked the sensitization of central TNC neurons with high thresholds but not those with wide dynamic range16,125; these effects were attributed to blockade of transmission between nociceptors and brainstem neurons rather than to suppression of spreading depolarization itself. This explanation is supported by evidence that monoclonal antibodies to CGRP do not suppress aura in people with migraine126 or propagation of spreading depolarization in animals127.

CGRP receptors are located on various cell types, including peripheral nerve terminals, immune cells, vasculature and satellite glial cells128, all of which might be affected by CGRP antagonists. Whether their effects on nociceptor activation induced by spreading depolarization are a result of central or peripheral mechanisms of action remains unclear. Now that generic versions of CGRP-targeted small molecules and monoclonal antibodies are commercially available, more preclinical studies are likely to emerge that could help to clarify this uncertainty.

Nonspecific treatments for pain used in migraine, such as the non-steroidal anti-inflammatory drug celecoxib, can also reverse the effect of spreading depolarization on some markers of meningeal inflammation; celecoxib reverses macrophage activation and meningeal artery dilation, but not plasma protein extravasation129. These data suggest that celecoxib not only reduces inflammation via COX-2 inhibition but can also reduce trigeminal activation with anti-migraine effects129. Finally, 1–2 weeks of treatment with botulinum toxin A, which inhibits synaptic vesicle release in sensory nerves and mostly from unmyelinated C-fibres, prolonged the latency of nociceptor responses to spreading depolarization130. Although this effect was observed after a short duration of treatment, it suggests an inhibitory effect on primary afferent nociceptors that could explain the analgesic effect of this drug.

Migraine drugs reduce associated pain behaviour

Trigeminal pain behaviour induced by spreading depolarization is also terminated by migraine treatments. For example, sumatriptan and the CGRP antagonist olcegepant reversed thermal hyperalgesia and photophobia-like behaviour induced by spreading depolarization in mice97. Similarly, in the minimally invasive optogenetic spreading depolarization model, sumatriptan pretreatment completely prevented allodynia20. In addition, valproate, which is used for migraine prevention131 and has abortive effects in humans132-134, reduced spreading depolarization-induced freezing behaviour and improved locomotion when administered as a single dose 30 min after spreading depolarization135. These data suggest that valproate can ameliorate surrogate pain behaviours caused by spreading depolarization. Taken together, these treatment effects demonstrate that the activation of nociceptive pathways by spreading depolarization and migraine-related pain behaviour are susceptible to migraine abortive and preventive medications.

Mechanisms of trigeminal nociceptor activation

The mechanisms by which spreading depolarization can lead to trigeminal activation and pain initiation are not clear. The pial and dural coverings of the cortex and proximal vessels contain peptidergic nociceptors that, when stimulated, can evoke a referred pain in the head136,137, defined as pain experienced in a location other than the site of stimulation in discrete regions of the head and neck (temporal, parietal, occipital, suboccipital or postauricular)131. The proximity of the cortex, and therefore spreading depolarization, to the overlying meningeal structures and their perivascular nerve endings could have a role in the referral of pain to the head, as opposed to other somatic regions. Passive diffusion of algogenic substances, release of nociceptive neurotransmitters and/or inflammation have all been proposed as mechanisms involved in trigeminal pain induced by spreading depolarization and are discussed below. Taken together, the bulk of evidence is consistent with a causal relationship between spreading depolarization and activation of trigeminal nociceptive pathways involved in migraine pain generation. Other mitigating events might alter the expression and pattern of pain responses in humans, but the available data indicate that spreading depression can be a trigger for head pain.

Passive diffusion

Substances released from neurons and glia during spreading depolarization, such as K+, nitric oxide, arachidonic acid metabolites, and other amino acids and cytokines, travel to the meningeal surface via bulk diffusion and can activate or sensitize trigeminal nerve endings that innervate pial and meningeal vessels58,138. The glymphatic system and meningeal lymphatic flow could facilitate communication of the parenchymal molecular perturbations to the dural sinuses139. The egress of interstitial fluid that contains algogenic substances can also activate a reservoir of myeloid cells in the skull bone marrow, which could theoretically be involved in meningeal and cortical responses to spreading depolarization128. Following spreading depolarization, cerebrospinal fluid can be transported via pathways of cerebrospinal fluid flow from the cortex into the trigeminal ganglion, where inflammatory mediators can directly activate trigeminal neurons140.

Peripheral inflammation

Trigeminal nociceptors can release a complement of neuropeptides, including CGRP and substance P, that mediate peripheral vascular changes that are hallmarks of inflammation, including increased vascular permeability and vasodilation141. Neurogenic inflammation (an increase in vessel leakage and dilation following antidromic stimulation of trigeminal afferent terminals) signifies neuropeptide release from perivascular peripheral nerve terminals141, and evidence suggests that this inflammation has a role in migraine headache. For example, both dense C fibres that contain CGRP and Aδ nerve fibres that express CGRP receptors innervate the dura142, and levels of CGRP and neurokinin A are increased in jugular venous blood flow at the beginning of a migraine attack143,144. However, plasma protein leakage that results from trigeminal activation is not a therapeutic target in itself145-149, as targeting this leakage in clinical trials with a neurokinin 1 antagonist148 and a triptan analogue with enhanced effects against neurogenic inflammation has been unsuccessful149,150. Furthermore, the involvement of neurogenic inflammation in migraine has been challenged151-153. Specifically, whether inflammation is involved in generating migraine or is a result of the invasive procedures used to model migraine in preclinical studies remains unclear, and the neuropeptides that produce peripheral inflammation in rodents (for example, substance P) differ from those that produce similar responses in humans (for example, CGRP). Given that substance P release and downstream vascular permeability do not seem to be targets for migraine therapy, whether neurogenic inflammation is a viable theory for migraine pain initiation remains uncertain153. Nonetheless, dural nociceptors innervate vessels that are in close proximity to perivascular dural mast cells, and trigeminal stimulation can evoke mast cell degranulation, which can contribute to meningeal inflammation154 and promote further meningeal nociceptor excitation155. The dura also contains diverse myeloid and lymphoid-derived immune cell populations, mostly macrophages or granulocytes (mast cells) and B cells156,157, but also dendritic cells, T cells and natural killer cells156-158. The crosstalk between dural nociceptors and these immune cells could theoretically contribute to dural afferent sensitization154,155,159-161.

Evidence has shown that spreading depolarization can certainly produce the cardinal features of peripheral inflammation, including ipsilateral middle meningeal artery dilation and plasma protein leakage and oedema in the dura162,163. Both are nullified by trigeminal nerve transection, suggesting that trigeminal afferent activity induced by spreading depolarization is the mechanism162. The effect of spreading depolarization on the middle meningeal artery and protein leakage mimics that of exogenous application of neuropeptides such as CGRP and tachykinins146,164. These data are consistent with spreading depolarization inducing a trigeminal afferent-driven dural inflammatory process, but whether meningeal inflammation drives the headache in migraine is not yet proven153. Spreading depolarization also alters the behaviour and morphology of meningeal immune cells165, but whether it directly activates immune cells or these changes occur indirectly as a result of nociceptor activation remains unclear.

Central inflammation

Spreading depolarization stimulates central neuroinflammation via a complex molecular cascade that involves immune cell activation and the release of inflammatory mediators into the brain parenchyma. Single or multiple spreading depolarization events activate pannexin 1 (PANX1) mega-channels166, which are involved in inflammatory responses and form a pore complex with the purinoceptor P2X7 receptor167. The importance of PANX1 in spreading depolarization is unclear, but it seems to have downstream effects on the activation of trigeminal nociceptors. In rodents, inhibition of P2X7 alone did not alter susceptibility to spreading depolarization168,169, but pharmacological inhibition of the P2X7–PANX1 complex did reduce susceptibility to spreading depolarization in one study168. Inhibition of PANX1 alone in rodents also did not affect spreading depolarization propagation166,169, dendritic beading during spreading depolarization or any of the commonly measured parameters of spreading depolarization (for example, duration and amplitude)170. Findings in relation to PANX1-mediated inflammation and trigeminal activation are more consistent. PANX1 opening mediated by spreading depolarization induces HMB1 translocation and NF-κB activation166, leads to late middle meningeal artery dilation and mast cell degranulation166, activation of an inflammasome complex that mediates neuroinflammation and increases CGRP expression171, and sensitization of trigeminal neurons169. In addition, acute171,172 and persistent glial cell activation171-173 has been observed as part of a neuroimmune response induced by spreading depolarization. In a study of people with migraine with aura, PET imaging showed high levels of glial activation in various brain regions173 and the parameningeal tissues (meninges and calvarial bone) during the interictal period, ~8 days after a migraine attack174, suggesting ictal and interictal abnormal neuroimmune activation.

Spreading depolarization as a therapeutic target

Currently available treatments for migraine include preventive interventions that reduce migraine attack frequency and abortive interventions that reduce or abolish migraine headache intensity when taken during an attack. A growing body of preclinical evidence indicates that spreading depolarization itself could be targeted in the treatment of migraine.

Migraine drugs and susceptibility to spreading depolarization

Studies in animals have demonstrated that the clinical efficacy of various preventive migraine treatments, including antiseizure drugs (topiramate and valproate), ergot alkaloids (methysergide), tricyclic antidepressants (amitriptyline) and others that block excess NMDA receptor activation (memantine and magnesium), is generally concordant with their ability to suppress spreading depolarization in preclinical models175. In a seminal study in rats176, susceptibility to spreading depolarization was decreased significantly after daily treatment for up to 17 weeks with topiramate (40–80 mg/kg daily), valproate (25–200 mg/kg daily), DL-propranolol (20 mg/kg daily), amitriptyline (10 or 20 mg/kg daily) and methysergide (0.1 or 1 mg/kg daily). These data were reproduced in later studies177-179. Furthermore, with topiramate and valproate, suppression of spreading depolarization was greater with longer drug exposure and higher doses176. By contrast, single doses of topiramate, valproate, propranolol or amitriptyline administered 1 h before testing did not suppress spreading depolarization176,177. In addition to a dose-dependent effect, efficacy increased with increased drug exposure. Chronic oral treatment with topiramate (50–600 mg/kg) in rats reduced susceptibility to spreading depolarization180. In another study, a single dose of topiramate (30 mg/kg) blocked mechanical induction of spreading depolarization in 60% of cats and 100% of rats; the inhibition became apparent within 10 min of drug administration but did not persist upon repeated mechanical stimulation 30 min later181. Drugs that do not have clinical efficacy in migraine have also been tested as negative controls. For example, inactive enantiomer d-propranolol (20 mg/kg daily) did not suppress spreading depolarization even after chronic treatment176. Similarly, oxcarbazepine, which is not clinically effective for migraine prevention182, did not affect susceptibility to spreading depolarization when administered as a 200 mg/kg single dose or 100 mg/kg daily for >5 weeks in rats177.

Given that NMDA glutamate receptors have a prominent role in spreading depolarization52,66,67,183-186, they have long been considered a potential therapeutic target in migraine, but the viability of this strategy — particularly for migraine prevention — is limited by adverse effects. For example, ketamine, which is a non-competitive NMDA receptor antagonist and dissociative anaesthetic, dose-dependently suppresses spreading depolarization in vivo and in vitro184,187-189, but its utility is limited by the high doses required to achieve this effect, which also cause anaesthesia190. Clinically, ketamine can reportedly reduce the severity of aura191, but intravenous administration of a single low dose for abortion of migraine did not affect numerical pain or functional disability scores and has been associated with adverse effects (insobriety, dizziness, fatigue, hallucinations, blurred vision and psychosis)192,193. However, repeated intranasal administration of ketamine in the emergency room had comparable efficacy to standard abortive treatments193, suggesting that its use for abortive migraine therapy could be feasible. Notably, ketamine seems to act at the level of trigeminal sensory processing, and therefore downstream of spreading depolarization194,195. Memantine is another non-competitive NMDA receptor antagonist196, and can suppress spreading depolarization196-198. In a study of 60 people with migraine without aura, memantine reduced monthly attack frequency, and in small randomized clinical trials that included 20–30 participants, memantine was also effective in people with migraine with and without aura199-201. Larger studies are needed to determine the validity of these findings.

Susceptibility to spreading depolarization and subsequent migraine also seems to be suppressed by magnesium202-204. The systemic administration of magnesium and increases in plasma levels of magnesium can increase extracellular magnesium concentrations in brain tissue205,206. In people with migraine with aura, acute magnesium infusion reduced headache intensity, photophobia and phonophobia, and lowered the likelihood of continued aura at 30 min and 60 min after drug administration compared with placebo207. The mechanism of action of magnesium on spreading depolarization is unclear, but in theory it could relate to magnesium blockade of NMDA receptors.

Not every drug that suppresses spreading depolarization in experimental models has demonstrated clinical efficacy in migraine; examples include lamotrigine178,208, gabapentin209,210 and tonabersat211. However, in the trials of lamotrigine and tonabersat, the baseline migraine frequency was very low, so a floor effect is possible. For example, in a single-centre, randomized, double-blind, placebo-controlled crossover study of tonabersat for migraine prevention, the trial included no run-in phase but the reported baseline number of headache days was 0.5–0.8 per week. Treatment with tonabersat was associated with a decrease in the interquartile range compared with placebo (1–5.4 versus 1–11) over the 3 months of treatment, but this difference did not reach statistical significance (P = 0.09)212. Notably, the number of aura attacks reduced substantially. A larger, multicentre study with more statistical power could be more conclusive with respect to the effects of these drugs.

Neuromodulation and spreading depolarization

In human studies, non-invasive vagal nerve stimulation (nVNS) reduced headache intensity and increased headache freedom when compared with sham stimulation213,214, and reduced the use of rescue medication215. In addition, an intention-to-treat analysis of episodic migraine prevention showed that nVNS reduced migraine and headache days, and this effect was strongest among people with migraine with aura216. In animal models, nVNS renders the cortex less susceptible to spreading depolarization within 30 min, and this effect is dependent on stimulus intensity and duration217. At a molecular level, nVNS twice for 2 min reversed the effects of spreading depolarization, such as increases in CGRP expression in the trigeminal ganglion, FOS expression in the TNC and COX-2 expression in the ipsilateral cortex218. These findings suggest that nVNS can decrease cortical excitability and downstream trigeminal nociceptor activation and could, therefore, be a useful anti-migraine treatment218. nVNS has these effects by activating vagal visceral sensory afferents that project to the brainstem nucleus tractus solitarius, which then activates serotonergic and norepinephrinergic neurons in the locus coeruleus and dorsal raphe219.

Whether magnetic stimulation affects susceptibility to spreading depolarization remains unclear, as there is a paucity of data in this area. In rats, single-pulse occipital direct magnetic stimulation through a craniectomy reduced the frequency of mechanically induced and KCl-induced spreading depolarization events; however, the same approach was ineffective in the gyrencephalic cat brain220. In the study of cats, occipital direct magnetic stimulation also inhibited thalamic, but not TNC, neuronal activation evoked by dural stimulation without spreading depolarization, possibly via corticothalamic projections, suggesting that spreading depolarization might not be the relevant target in migraine220. In rodents, two single-pulse transcranial magnetic stimulations (sTMSs) increased the electrical threshold for spreading depolarization221. Two clinical studies of daily sTMS suggested beneficial effects in migraine, but these studies were not randomized, blinded, placebo-controlled trials222,223. One randomized, blinded, placebo-controlled trial did show that sTMS alleviated migraine headache when administered just after aura onset224, and two others showed that high-frequency repetitive prophylactic TMS reduced attack frequency and headache intensity225,226.

Translational value of spreading depolarization

Targeting susceptibility to spreading depolarization

Given that preclinical and clinical data suggest that spreading depolarization underlies aura symptoms and can trigger trigeminal nociception, much research in the past two decades has focused on discovering interventions that reduce the susceptibility of brain tissue to spreading depolarization and could therefore be effective for migraine prophylaxis, at least in a subset of people with migraine227. Experimental models used for this work, which have been reviewed in detail elsewhere186,228,229, are based on the principle that spreading depolarization is triggered when a threshold excitation or depolarization level is reached. The threshold can be determined by gradually increasing the intensity of the chosen stimulus (for example, cathodal pulses, high K+ solutions or optogenetic illumination), and interventions can be tested for their ability to raise the threshold (Fig. 3). Such high-throughput translational rodent models can be used to screen for therapeutics, not only for migraine but also for other conditions in which spreading depolarization is thought to contribute to the outcome, such as ischaemic, haemorrhagic or traumatic brain injury.

Fig. 3 ∣. Spreading depolarization as a high-throughput translational model for preventive migraine drug screening.

Fig. 3 ∣

The susceptibility to spreading depolarization and its response to preventive treatments can be determined with the electrical and chemical induction paradigms shown, in which spreading depolarization is recorded with electrodes (DC1 and DC2) placed on or in grey matter (for example, the cerebral cortex). a, A paradigm for testing drug effects on susceptibility to spreading depolarization by measuring the electrical threshold. Spreading depolarization is induced by electrical stimulation through a craniotomy (left). The threshold for spreading depolarization is determined by increasing the current amplitude and duration until spreading depolarization is evoked (middle). A drug that increases this threshold reduces the susceptibility to spreading depolarization (right) and is therefore a candidate for the prevention of migraine with aura. b, A paradigm for testing drug effects on susceptibility to spreading depolarization by measuring the frequency of spreading depolarization. Spreading depolarization is induced by topical application of 1 M KCl (left). Frequency is determined by counting the number of spreading depolarization events evoked by continuous application over a given time (middle). A drug that reduces the frequency of spreading depolarization reduces susceptibility to spreading depolarization (right) and is therefore a candidate for the prevention of migraine with aura. DC, direct current; ECoG, electrocorticography. The graphs are based on data from ref. 230.

Targeting trigeminal nociception and behavioural changes

Non-invasive optogenetic induction of spreading depolarization in rodents leads to the activation of trigeminal nociceptors and associated neurobehavioural features that mimic migraine, making this approach an attractive translational animal model in which to test interventions that target pathways downstream of spreading depolarization and abort migraine attacks20. Acute behavioural outcomes induced by spreading depolarization that can be used as high-throughput screens to test acute drug targets include evoked pain in the periorbital area (periorbital allodynia), spontaneous pain (facial grimace), heightened facial grimace to light or light aversion as a measure of photosensitivity, and other emotional responses and alterations in motor behaviours (Fig. 4). Indeed, in the optogenetic spreading depolarization model, neurobehavioural features of migraine can be modulated by abortive drugs, such as triptans, and female hormones230-232. Recent advances that obviate the need for anaesthesia increase the translational potential of the model, as there is no confounding effect of anaesthesia and spreading depolarization can be induced in the awake state233. Further refinements, such as restricting holohemispheric spreading depolarization to a smaller region to more accurately mimic the process of spreading depolarization in the human brain and examining the effects on more complex behaviour (for example, social interactions and conditioned place preference) will undoubtedly make the model even more useful. Implementing machine learning through the use of convolutional neural networks to assess pain behaviour outcomes, such as grimace, would reduce the burden and bias of manual scoring and increase the throughput for therapeutic testing234.

Fig. 4 ∣. Spreading depolarization as a high-throughput translational model for abortive migraine drug screening using migraine-relevant behaviour.

Fig. 4 ∣

a, A paradigm for testing drug effects on trigeminal pain. Periorbital mechanical thresholds are tested with calibrated von Frey monofilaments to test periorbital allodynia in treated and untreated animals in the presence and absence of spreading depolarization (left). Induced spreading depolarization produces an acute periorbital allodynia (a reduction in mechanical threshold compared with sham-treated controls; middle). Reversal of this reduction in threshold by sumatriptan (right) shows that spreading depression can be used as a screening tool for acute migraine treatments20. b, A paradigm for testing drug effects on pain by monitoring grimace behaviour. Following spreading depolarization, the grimace response is scored manually or with artificial intelligence analysis (left). Higher scores indicate greater pain. Chronic spreading depolarization leads to a higher grimace score (right) and drugs can be tested for their ability to reverse this increase20. c, A paradigm for testing drug effects on photosensitivity by monitoring grimace behaviour. Animals are exposed to light of different brightness, and a higher grimace score indicates greater photosensitivity20,232 (left). Spreading depolarization increases grimace scores in response to the same brightness of light, and drugs can be tested for their ability to reverse this increase. Graphs in parts a and b based on data from ref. 20. Graph in part c based on data from ref. 232.

Conclusions

Decades of evidence indicate that spreading depolarization underlies migraine aura, can activate trigeminal nociceptors and can increase trigeminal pain behaviour that responds to migraine therapies. Multiple questions remain, such as the cause and triggers for spreading depolarization in the healthy brain, the propagation patterns for spreading depolarization in different gyrencephalic cortical brain regions and the mechanisms induced by spreading depolarization that lead to trigeminal pain. The refinement of models of spreading depolarization will help to address these questions. For example, in emerging animal studies, the use of awake and repeated spreading depolarization could provide insight into the mechanisms of chronic migraine with aura and its effect on pain and other phenotypes (sensitivity to light, sound, vestibular dysfunction, cardiovascular and cerebrovascular outcomes), as well as the roles of sex and ageing in migraine disease progression. In humans, the ongoing challenge to capture and record spreading depolarization events will shape disease definition and shed light on aspects such as silent spreading depolarization. Given that current clinical and preclinical evidence supports the notion that spreading depolarization has a biological role in the pathogenesis of migraine aura and migraine pain, and suggests that spreading depolarization and its downstream events (for example, activation of trigeminal nociceptors) are targets for migraine therapies, future research should focus on spreading depolarization as a screening tool for abortive and preventive migraine therapies.

Footnotes

Competing interests

A.M.H. serves on the board of directors for the Headache Cooperative of New England, the American Migraine Foundation and the American Headache Society, and has received compensation from Abbvie and Theranica for participation on scientific advisory boards. C.A. declares no competing interests.

Peer review information Nature Reviews Neurology thanks A. Andreou, T. Dalkara, D.

Pietrobon, M. Shibata and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

References

  • 1.Vos T. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1211–1259 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Stovner LJ et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 17, 954–976 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Bonafede M. et al. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache 58, 700–714 (2018). [DOI] [PubMed] [Google Scholar]
  • 4.Burch R, Rizzoli P & Loder E The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache 58, 496–505 (2018). [DOI] [PubMed] [Google Scholar]
  • 5.Burch RC, Buse DC & Lipton RB Migraine: epidemiology, burden, and comorbidity. Neurol. Clin 37, 631–649 (2019). [DOI] [PubMed] [Google Scholar]
  • 6.Lipton RB et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68, 343–349 (2007). [DOI] [PubMed] [Google Scholar]
  • 7.Headache classification committee of the international headache society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia 10.1177/0333102417738202 (2018). [DOI] [PubMed] [Google Scholar]
  • 8.Andress-Rothrock D, King W & Rothrock J An analysis of migraine triggers in a clinic-based population. Headache 50, 1366–1370 (2010). [DOI] [PubMed] [Google Scholar]
  • 9.Lipton RB et al. Identifying natural subgroups of migraine based on comorbidity and concomitant condition prof iles: results of the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 58, 933–947 (2018). [DOI] [PubMed] [Google Scholar]
  • 10.Leao AAP Spreading depression of activity in cerebral cortex. J. Neurophysiol 7, 359–390 (1944). [DOI] [PubMed] [Google Scholar]
  • 11.Lashley KS Patterns of cerebral integration indicated by the scotomas of migraine. Arch. Neurol. Psychiatry 46, 331–339 (1941). [Google Scholar]
  • 12.Leao AAP & Morison RS Propagation of spreading cortical depression. J. Neurophysiol 8, 33–45 (1945). [Google Scholar]
  • 13.Hadjikhani N. et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc. Natl Acad. Sci. USA 98, 4687–4692 (2001). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Moskowitz MA, Nozaki K & Kraig RP Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J. Neurosci 13, 1167–1177 (1993). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Zhang X. et al. Activation of central trigeminovascular neurons by cortical spreading depression. Ann. Neurol 69, 855–865 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Melo-Carrillo A. et al. Selective inhibition of trigeminovascular neurons by fremanezumab: a humanized monoclonal anti-CGRP antibody. J. Neurosci 37, 7149–7163 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Zhang X. et al. Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J. Neurosci 30, 8807–8814 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Filiz A. et al. CGRP receptor antagonist MK-8825 attenuates cortical spreading depression induced pain behavior. Cephalalgia 39, 354–365 (2019). [DOI] [PubMed] [Google Scholar]
  • 19.Cottier KE et al. Loss of blood–brain barrier integrity in a Kcl-induced model of episodic headache enhances CNS drug delivery. eNeuro 10.1523/ENEURO.0116-18.2018 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Harriott AM et al. Optogenetic spreading depression elicits trigeminal pain and anxiety behavior. Ann. Neurol 89, 99–110 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Rodgers CI, Armstrong GA & Robertson RM Coma in response to environmental stress in the locust: a model for cortical spreading depression. J. Insect Physiol 56, 980–990 (2010). [DOI] [PubMed] [Google Scholar]
  • 22.Andersen MK, Willot Q & MacMillan HA A neurophysiological limit and its biogeographic correlations: cold-induced spreading depolarization in tropical butterflies. J. Exp. Biol 226, jeb246313 (2023). [DOI] [PubMed] [Google Scholar]
  • 23.Robertson RM, Dawson-Scully KD & Andrew RD Neural shutdown under stress: an evolutionary perspective on spreading depolarization. J. Neurophysiol 123, 885–895 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Gorji A. et al. Spreading depression in human neocortical slices. Brain Res. 906, 74–83 (2001). [DOI] [PubMed] [Google Scholar]
  • 25.Strong AJ et al. Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke 33, 2738–2743 (2002). [DOI] [PubMed] [Google Scholar]
  • 26.McLeod GA, Josephson CB, Engbers JDT, Cooke LJ & Wiebe S Mapping the migraine: intracranial recording of cortical spreading depression in migraine with aura. Headache 65, 658–665 (2025). [DOI] [PubMed] [Google Scholar]
  • 27.Rasmussen BK & Olesen J Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 12, 221–228 (1992). [DOI] [PubMed] [Google Scholar]
  • 28.Buse DC et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache 53, 1278–1299 (2013). [DOI] [PubMed] [Google Scholar]
  • 29.Lipton RB et al. Cutaneous allodynia in the migraine population. Ann. Neurol 63, 148–158 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Lovati C. et al. Allodynia in different forms of migraine. Neurol. Sci 28, S220–S221 (2007). [DOI] [PubMed] [Google Scholar]
  • 31.Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ & Bajwa ZH An association between migraine and cutaneous allodynia. Ann. Neurol 47, 614–624 (2000). [PubMed] [Google Scholar]
  • 32.LoPinto C, Young WB & Ashkenazi A Comparison of dynamic (brush) and static (pressure) mechanical allodynia in migraine. Cephalalgia 26, 852–856 (2006). [DOI] [PubMed] [Google Scholar]
  • 33.Oedegaard KJ et al. Migraine with and without aura: association with depression and anxiety disorder in a population-based study. The HUNT study. Cephalalgia 26, 1–6 (2006). [DOI] [PubMed] [Google Scholar]
  • 34.Kim KM et al. Prevalence and impact of visual aura in migraine and probable migraine: a population study. Sci. Rep 12, 426 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Lipton RB et al. Allodynia is associated with initial and sustained response to acute migraine treatment: results from the American Migraine Prevalence and Prevention study. Headache 57, 1026–1040 (2017). [DOI] [PubMed] [Google Scholar]
  • 36.Viana M. et al. Clinical features of migraine aura: results from a prospective diary-aided study. Cephalalgia 37, 979–989 (2017). [DOI] [PubMed] [Google Scholar]
  • 37.Russell MB & Olesen J A nosographic analysis of the migraine aura in a general population. Brain 119, 355–361 (1996). [DOI] [PubMed] [Google Scholar]
  • 38.Hansen JM, Goadsby PJ & Charles AC Variability of clinical features in attacks of migraine with aura. Cephalalgia 36, 216–224 (2016). [DOI] [PubMed] [Google Scholar]
  • 39.Airy H. On a distinct form of transient hemiopsia. Philos. Trans. R. Soc. Lond 160, 247–264 (1870). [Google Scholar]
  • 40.Viana M, Tronvik EA, Do TP, Zecca C & Hougaard A Clinical features of visual migraine aura: a systematic review. J. Headache Pain 20, 64 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Petrusic I, Pavlovski V, Vucinic D & Jancic J Features of migraine aura in teenagers. J. Headache Pain 15, 87 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Kelman L. The aura: a tertiary care study of 952 migraine patients. Cephalalgia 24, 728–734 (2004). [DOI] [PubMed] [Google Scholar]
  • 43.Ahmed MA, Donaldson S, Akor F, Cahill D & Akilani R Olfactory hallucination in childhood primary headaches: case series. Cephalalgia 35, 234–239 (2015). [DOI] [PubMed] [Google Scholar]
  • 44.Henkin RI, Potolicchio SJ & Levy LM Olfactory hallucinations without clinical motor activity: a comparison of unirhinal with birhinal phantosmia. Brain Sci. 3, 1483–1553 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Barrett CF, van den Maagdenberg A, Frants RR & Ferrari MD Familial hemiplegic migraine. Adv. Genet 63, 57–83 (2008). [DOI] [PubMed] [Google Scholar]
  • 46.Sutherland HG, Jenkins B & Griffiths LR Genetics of migraine: complexity, implications, and potential clinical applications. Lancet Neurol. 23, 429–446 (2024). [DOI] [PubMed] [Google Scholar]
  • 47.Gosalia H, Karsan N & Goadsby PJ Genetic mechanisms of migraine: insights from monogenic migraine mutations. Int. J. Mol. Sci 24, 12697 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Pietrobon D & Moskowitz MA Pathophysiology of migraine. Annu. Rev. Physiol 75, 365–391 (2013). [DOI] [PubMed] [Google Scholar]
  • 49.Terwindt GM, Ophoff RA, Haan J, Frants RR & Ferrari MD Familial hemiplegic migraine: a clinical comparison of families linked and unlinked to chromosome 19.DMG RG. Cephalalgia 16, 153–155 (1996). [DOI] [PubMed] [Google Scholar]
  • 50.Joutel A. et al. A gene for familial hemiplegic migraine maps to chromosome 19. Nat. Genet 5, 40–45 (1993). [DOI] [PubMed] [Google Scholar]
  • 51.Hartings JA et al. The continuum of spreading depolarizations in acute cortical lesion development: examining Leao’s legacy. J. Cereb. Blood Flow Metab 10.1177/0271678X16654495 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Pietrobon D & Moskowitz MA Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations. Nat. Rev. Neurosci 15, 379–393 (2014). [DOI] [PubMed] [Google Scholar]
  • 53.Somjen GG Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. Physiol. Rev 81, 1065–1096 (2001). [DOI] [PubMed] [Google Scholar]
  • 54.Ayata C & Lauritzen M Spreading depression, spreading depolarizations, and the cerebral vasculature. Physiol. Rev 95, 953–993 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Dreier JP The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat. Med 17, 439–447 (2011). [DOI] [PubMed] [Google Scholar]
  • 56.Eikermann-Haerter K. et al. Abnormal synaptic Ca2+ homeostasis and morphology in cortical neurons of familial hemiplegic migraine type 1 mutant mice. Ann. Neurol 78, 193–210 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Peters O, Schipke CG, Hashimoto Y & Kettenmann H Different mechanisms promote astrocyte Ca2+ waves and spreading depression in the mouse neocortex. J. Neurosci 23, 9888–9896 (2003). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Fabricius M, Jensen LH & Lauritzen M Microdialysis of interstitial amino acids during spreading depression and anoxic depolarization in rat neocortex. Brain Res. 612, 61–69 (1993). [DOI] [PubMed] [Google Scholar]
  • 59.Lindquist BE & Shuttleworth CW Adenosine receptor activation is responsible for prolonged depression of synaptic transmission after spreading depolarization in brain slices. Neuroscience 223, 365–376 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Seidel JL, Escartin C, Ayata C, Bonvento G & Shuttleworth CW Multifaceted roles for astrocytes in spreading depolarization: a target for limiting spreading depolarization in acute brain injury? Glia 64, 5–20 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Grafstein B. Subverting the hegemony of the synapse: complicity of neurons, astrocytes, and vasculature in spreading depression and pathology of the cerebral cortex. Brain Res. Rev 66, 123–132 (2010). [DOI] [PubMed] [Google Scholar]
  • 62.Grafstein B. Locus of propagation of spreading cortical depression. J. Neurophysiol 19, 308–316 (1956). [DOI] [PubMed] [Google Scholar]
  • 63.Hansen AJ & Zeuthen T Extracellular ion concentrations during spreading depression and ischemia in the rat brain cortex. Acta Physiol. Scand 113, 437–445 (1981). [DOI] [PubMed] [Google Scholar]
  • 64.Obrenovitch TP & Zilkha E High extracellular potassium, and not extracellular glutamate, is required for the propagation of spreading depression. J. Neurophysiol 73, 2107–2114 (1995). [DOI] [PubMed] [Google Scholar]
  • 65.Marrannes R, Willems R, De Prins E & Wauquier A Evidence for a role of the N-methyl-d-aspartate (NMDA) receptor in cortical spreading depression in the rat. Brain Res. 457, 226–240 (1988). [DOI] [PubMed] [Google Scholar]
  • 66.Masvidal-Codina E et al. Characterization of optogenetically-induced cortical spreading depression in awake mice using graphene micro-transistor arrays. J. Neural Eng 10.1088/1741-2552/abecf3 (2021). [DOI] [PubMed] [Google Scholar]
  • 67.Crivellaro G. et al. Specific activation of GluN1-N2B NMDA receptors underlies facilitation of cortical spreading depression in a genetic mouse model of migraine with reduced astrocytic glutamate clearance. Neurobiol. Dis 156, 105419 (2021). [DOI] [PubMed] [Google Scholar]
  • 68.Mody I, Lambert JD & Heinemann U Low extracellular magnesium induces epileptiform activity and spreading depression in rat hippocampal slices. J. Neurophysiol 57, 869–888 (1987). [DOI] [PubMed] [Google Scholar]
  • 69.Santos E. et al. Radial, spiral and reverberating waves of spreading depolarization occur in the gyrencephalic brain. Neuroimage 99, 244–255 (2014). [DOI] [PubMed] [Google Scholar]
  • 70.Santos E, Sanchez-Porras R, Sakowitz OW, Dreier JP & Dahlem MA Heterogeneous propagation of spreading depolarizations in the lissencephalic and gyrencephalic brain. J. Cereb. Blood Flow Metab 37, 2639–2643 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Cain SM et al. In vivo imaging reveals that pregabalin inhibits cortical spreading depression and propagation to subcortical brain structures. Proc. Natl Acad. Sci. USA 114, 2401–2406 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Vinogradova LV, Koroleva VI & Bures J Re-entry waves of Leao’s spreading depression between neocortex and caudate nucleus. Brain Res. 538, 161–164 (1991). [DOI] [PubMed] [Google Scholar]
  • 73.Bures J, Buresova O, Fifkova E & Rabending G Reversible deafferentation of cerebral cortex by thalamic spreading depression. Exp. Neurol 12, 55–67 (1965). [DOI] [PubMed] [Google Scholar]
  • 74.Yuzawa I. et al. Cortical spreading depression impairs oxygen delivery and metabolism in mice. J. Cereb. Blood Flow Metab 32, 376–386 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Ayata C. et al. Pronounced hypoperfusion during spreading depression in mouse cortex. J. Cereb. Blood Flow Metab 24, 1172–1182 (2004). [DOI] [PubMed] [Google Scholar]
  • 76.Ostergaard L. et al. Neurovascular coupling during cortical spreading depolarization and -depression. Stroke 46, 1392–1401 (2015). [DOI] [PubMed] [Google Scholar]
  • 77.Ayata C. Spreading depression and neurovascular coupling. Stroke 44, S87–S89 (2013). [DOI] [PubMed] [Google Scholar]
  • 78.Sadeghian H. et al. Spreading depolarizations trigger caveolin-1-dependent endothelial transcytosis. Ann. Neurol 84, 409–423 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Cha YH, Millett D, Kane M, Jen J & Baloh R Adult-onset hemiplegic migraine with cortical enhancement and oedema. Cephalalgia 27, 1166–1170 (2007). [DOI] [PubMed] [Google Scholar]
  • 80.Dreier JP et al. Opening of the blood–brain barrier preceding cortical edema in a severe attack of FHM type II. Neurology 64, 2145–2147 (2005). [DOI] [PubMed] [Google Scholar]
  • 81.Kors EE et al. Delayed cerebral edema and fatal coma after minor head trauma: role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine. Ann. Neurol 49, 753–760 (2001). [DOI] [PubMed] [Google Scholar]
  • 82.Hougaard A. et al. Increased brainstem perfusion, but no blood–brain barrier disruption, during attacks of migraine with aura. Brain 140, 1633–1642 (2017). [DOI] [PubMed] [Google Scholar]
  • 83.Amin FM et al. Intact blood–brain barrier during spontaneous attacks of migraine without aura: a 3T DCE-MRI study. Eur. J. Neurol 24, 1116–1124 (2017). [DOI] [PubMed] [Google Scholar]
  • 84.Schain AJ, Melo-Carrillo A, Strassman AM & Burstein R Cortical spreading depression closes paravascular space and impairs glymphatic flow: implications for migraine headache. J. Neurosci 37, 2904–2915 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Takizawa T. et al. Non-invasively triggered spreading depolarizations induce a rapid pro-inflammatory response in cerebral cortex. J. Cereb. Blood Flow Metab 10.1177/0271678X19859381 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Dell'Orco M. et al. Repetitive spreading depolarization induces gene expression changes related to synaptic plasticity and neuroprotective pathways. Front. Cell. Neurosci 14, 1292661 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Caggiano AO & Kraig RP Eicosanoids and nitric oxide influence induction of reactive gliosis from spreading depression in microglia but not astrocytes. J. Comp. Neurol 369, 93–108 (1996). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Kraig RP, Dong LM, Thisted R & Jaeger CB Spreading depression increases immunohistochemical staining of glial fibrillary acidic protein. J. Neurosci 11, 2187–2198 (1991). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Escartin C. et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat. Neurosci 24, 312–325 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Yang L. et al. Human and mouse trigeminal ganglia cell atlas implicates multiple cell types in migraine. Neuron 110, 1806–1821 e1808 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Sukhotinsky I. et al. Chronic daily cortical spreading depressions suppress spreading depression susceptibility. Cephalalgia 31, 1601–1608 (2011). [DOI] [PubMed] [Google Scholar]
  • 92.Nedergaard M & Hansen AJ Spreading depression is not associated with neuronal injury in the normal brain. Brain Res. 449, 395–398 (1988). [DOI] [PubMed] [Google Scholar]
  • 93.Dreier JP et al. Recording, analysis, and interpretation of spreading depolarizations in neurointensive care: review and recommendations of the COSBID research group. J. Cereb. Blood Flow Metab 37, 1595–1625 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Suryavanshi P, Reinhart KM, Shuttleworth CW & Brennan KC Action potentials are critical for the propagation of focally elicited spreading depolarizations. J. Neurosci 42, 2371–2383 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Eikermann-Haerter K, Can A & Ayata C Pharmacological targeting of spreading depression in migraine. Expert Rev. Neurother 12, 297–306 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Takizawa T. et al. Non-invasively triggered spreading depolarizations induce a rapid pro-inflammatory response in cerebral cortex. J. Cereb. Blood Flow Metab 40, 1117–1131 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Tang C. et al. Cortical spreading depolarisation-induced facial hyperalgesia, photophobia and hypomotility are ameliorated by sumatriptan and olcegepant. Sci. Rep 10, 11408 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Milner PM Note on a possible correspondence between the scotomas of migraine and spreading depression of Leao. Electroencephalogr. Clin. Neurophysiol 10, 705 (1958). [DOI] [PubMed] [Google Scholar]
  • 99.Olesen J, Larsen B & Lauritzen M Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann. Neurol 9, 344–352 (1981). [DOI] [PubMed] [Google Scholar]
  • 100.Lauritzen M, Olsen TS, Lassen NA & Paulson OB Regulation of regional cerebral blood flow during and between migraine attacks. Ann. Neurol 14, 569–572 (1983). [DOI] [PubMed] [Google Scholar]
  • 101.Lauritzen M, Skyhoj Olsen T, Lassen NA & Paulson OB Changes in regional cerebral blood flow during the course of classic migraine attacks. Ann. Neurol 13, 633–641 (1983). [DOI] [PubMed] [Google Scholar]
  • 102.O’Brien MD Cerebral-cortex-perfusion rates in migraine. Lancet 1, 1036 (1967). [DOI] [PubMed] [Google Scholar]
  • 103.Dreier JP & Reiffurth C The stroke-migraine depolarization continuum. Neuron 86, 902–922 (2015). [DOI] [PubMed] [Google Scholar]
  • 104.Bowyer SM, Aurora KS, Moran JE, Tepley N & Welch KM Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann. Neurol 50, 582–587 (2001). [DOI] [PubMed] [Google Scholar]
  • 105.Barkley GL et al. Magnetoencephalographic studies of migraine. Headache 30, 428–434 (1990). [DOI] [PubMed] [Google Scholar]
  • 106.Bowyer SM et al. Analysis of MEG signals of spreading cortical depression with propagation constrained to a rectangular cortical strip. II. Gyrencephalic swine model. Brain Res. 843, 79–86 (1999). [DOI] [PubMed] [Google Scholar]
  • 107.Wijesinghe RS & Tepley N A four sphere model for calculating the magnetic field associated with spreading cortical depression. Brain Topogr. 9, 191–202 (1997). [DOI] [PubMed] [Google Scholar]
  • 108.Bolay H, Vuralli D & Goadsby PJ Aura and Head pain: relationship and gaps in the translational models. J. Headache Pain 20, 94 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Bahra A, Matharu MS, Buchel C, Frackowiak RS & Goadsby PJ Brainstem activation specific to migraine headache. Lancet 357, 1016–1017 (2001). [DOI] [PubMed] [Google Scholar]
  • 110.Weiller C. et al. Brain stem activation in spontaneous human migraine attacks. Nat. Med 1, 658–660 (1995). [DOI] [PubMed] [Google Scholar]
  • 111.Schulte LH & May A Of generators, networks and migraine attacks. Curr. Opin. Neurol 30, 241–245 (2017). [DOI] [PubMed] [Google Scholar]
  • 112.Thomsen AV et al. Clinical features of migraine with aura: a REFORM study. J. Headache Pain 25, 22 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Hansen JM et al. Migraine headache is present in the aura phase: a prospective study. Neurology 79, 2044–2049 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Eriksen MK, Thomsen LL & Olesen J Sensitivity and specificity of the new international diagnostic criteria for migraine with aura. J. Neurol. Neurosurg. Psychiatry 76, 212–217 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Arngrim N. et al. Heterogenous migraine aura symptoms correlate with visual cortex functional magnetic resonance imaging responses. Ann. Neurol 82, 925–939 (2017). [DOI] [PubMed] [Google Scholar]
  • 116.Olesen J. et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann. Neurol 28, 791–798 (1990). [DOI] [PubMed] [Google Scholar]
  • 117.Lambert GA, Truong L & Zagami AS Effect of cortical spreading depression on basal and evoked traffic in the trigeminovascular sensory system. Cephalalgia 31, 1439–1451 (2011). [DOI] [PubMed] [Google Scholar]
  • 118.Burstein R, Strassman A & Moskowitz M Can cortical spreading depression activate central trigeminovascular neurons without peripheral input? Pitfalls of a new concept. Cephalalgia 32, 509–511 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Zhao J & Levy D Cortical spreading depression promotes persistent mechanical sensitization of intracranial meningeal afferents: implications for the intracranial mechanosensitivity of migraine. eNeuro 10.1523/ENEURO.0287-16.2016 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120.Fioravanti B. et al. Evaluation of cutaneous allodynia following induction of cortical spreading depression in freely moving rats. Cephalalgia 31, 1090–1100 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Han SM et al. Prevalence and characteristics of cutaneous allodynia in probable migraine. Sci. Rep 11, 2467 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Langford DJ et al. Coding of facial expressions of pain in the laboratory mouse. Nat. Methods 7, 447–449 (2010). [DOI] [PubMed] [Google Scholar]
  • 123.Strassman AM et al. Atogepant — an orally-administered CGRP antagonist — attenuates activation of meningeal nociceptors by CSD. Cephalalgia 42, 933–943 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Melo-Carrillo A. et al. Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons. Cephalalgia 41, 17–32 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125.Melo-Carrillo A. et al. Fremanezumab-A humanized monoclonal anti-CGRP antibodyinhibits thinly myelinated (aδ) but not unmyelinated (C) meningeal nociceptors. J. Neurosci 37, 10587–10596 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Cresta E, Bellotti A, Rinaldi G, Corbelli I & Sarchielli P Effect of anti-CGRP-targeted therapy on migraine aura: results of an observational case series study. CNS Neurosci. Ther 30, e14595 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Melo-Carrillo A, Schain AJ, Stratton J, Strassman AM & Burstein R Fremanezumab and its isotype slow propagation rate and shorten cortical recovery period but do not prevent occurrence of cortical spreading depression in rats with compromised blood–brain barrier. Pain 161, 1037–1043 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128.Levy D & Moskowitz MA Meningeal mechanisms and the migraine connection. Annu. Rev. Neurosci 46, 39–58 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129.Schain AJ, Melo-Carrillo A, Ashina S, Strassman AM & Burstein R Celecoxib reduces cortical spreading depression-induced macrophage activation and dilatation of dural but not pial arteries in rodents: implications for mechanism of action in terminating migraine attacks. Pain 161, 1019–1026 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Melo-Carrillo A. et al. Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats. Cephalalgia 39, 1358–1365 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131.Ailani J, Burch RC, Robbins MS & Board of Directors of the American Headache Society The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61, 1021–1039 (2021). [DOI] [PubMed] [Google Scholar]
  • 132.Mathew NT, Kailasam J, Meadors L, Chernyschev O & Gentry P Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache 40, 720–723 (2000). [DOI] [PubMed] [Google Scholar]
  • 133.Edwards KR, Norton J & Behnke M Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache 41, 976–980 (2001). [DOI] [PubMed] [Google Scholar]
  • 134.Bakhshayesh B, Seyed Saadat SM, Rezania K, Hatamian H & Hossieninezhad M A randomized open-label study of sodium valproate vs sumatriptan and metoclopramide for prolonged migraine headache. Am. J. Emerg. Med 31, 540–544 (2013). [DOI] [PubMed] [Google Scholar]
  • 135.Tepe N. et al. The thalamic reticular nucleus is activated by cortical spreading depression in freely moving rats: prevention by acute valproate administration. Eur. J. Neurosci 41, 120–128 (2015). [DOI] [PubMed] [Google Scholar]
  • 136.Fontaine D. et al. Dural and pial pain-sensitive structures in humans: new inputs from awake craniotomies. Brain 141, 1040–1048 (2018). [DOI] [PubMed] [Google Scholar]
  • 137.Ray BWH Experimental studies on headache: pain-sensitive structures of the head and their significance in headache. Arch. Surg 41, 813–856 (1940). [Google Scholar]
  • 138.Lauritzen M, Hansen AJ, Kronborg D & Wieloch T Cortical spreading depression is associated with arachidonic acid accumulation and preservation of energy charge. J. Cereb. Blood Flow Metab 10, 115–122 (1990). [DOI] [PubMed] [Google Scholar]
  • 139.Rustenhoven J. et al. Functional characterization of the dural sinuses as a neuroimmune interface. Cell 184, 1000–1016.e1027 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 140.Kaag Rasmussen M. et al. Trigeminal ganglion neurons are directly activated by influx of CSF solutes in a migraine model. Science 385, 80–86 (2024). [DOI] [PubMed] [Google Scholar]
  • 141.Harriott AM & Orlova Y Anatomy and physiology of headache. Semin. Neurol 42, 459–473 (2022). [DOI] [PubMed] [Google Scholar]
  • 142.Eftekhari S, Warfvinge K, Blixt FW & Edvinsson L Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J. Pain 14, 1289–1303 (2013). [DOI] [PubMed] [Google Scholar]
  • 143.Goadsby PJ, Edvinsson L & Ekman R Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol 28, 183–187 (1990). [DOI] [PubMed] [Google Scholar]
  • 144.Gallai V. et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 15, 384–390 (1995). [DOI] [PubMed] [Google Scholar]
  • 145.O’Shaughnessy CT & Connor HE Investigation of the role of tachykinin NK1, NK2 receptors and CGRP receptors in neurogenic plasma protein extravasation in dura mater. Eur. J. Pharmacol 263, 193–198 (1994). [DOI] [PubMed] [Google Scholar]
  • 146.Markowitz S, Saito K & Moskowitz MA Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J. Neurosci 7, 4129–4136 (1987). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 147.Lee WS, Moussaoui SM & Moskowitz MA Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva. Br. J. Pharmacol 112, 920–924 (1994). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 148.Goldstein DJ et al. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 17, 785–790 (1997). [DOI] [PubMed] [Google Scholar]
  • 149.Roon KI et al. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. Ann. Neurol 47, 238–241 (2000). [PubMed] [Google Scholar]
  • 150.Lee WS & Moskowitz MA Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638 exhibit enhanced potency against neurogenic inflammation in dura mater. Brain Res. 626, 303–305 (1993). [DOI] [PubMed] [Google Scholar]
  • 151.Moskowitz MA, Reinhard JF Jr., Romero J, Melamed E & Pettibone DJ Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine? Lancet 2, 883–885 (1979). [DOI] [PubMed] [Google Scholar]
  • 152.Edvinsson L, Haanes KA & Warfvinge K Does inflammation have a role in migraine? Nat. Rev. Neurol 15, 483–490 (2019). [DOI] [PubMed] [Google Scholar]
  • 153.Charles A, Nwaobi SE & Goadsby P Inflammation in migraine…or not…: a critical evaluation of the evidence. Headache 61, 1575–1578 (2021). [DOI] [PubMed] [Google Scholar]
  • 154.Dimitriadou V, Buzzi MG, Moskowitz MA & Theoharides TC Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 44, 97–112 (1991). [DOI] [PubMed] [Google Scholar]
  • 155.Levy D, Burstein R, Kainz V, Jakubowski M & Strassman AM Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 130, 166–176 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 156.McIlvried LA, Cruz JA, Borghesi LA & Gold MS Sex-, stress-, and sympathetic post-ganglionic-dependent changes in identity and proportions of immune cells in the dura. Cephalalgia 37, 36–48 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 157.Dimlich RV, Keller JT, Strauss TA & Fritts MJ Linear arrays of homogeneous mast cells in the dura mater of the rat. J. Neurocytol 20, 485–503 (1991). [DOI] [PubMed] [Google Scholar]
  • 158.McMenamin PG Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. J. Comp. Neurol 405, 553–562 (1999). [PubMed] [Google Scholar]
  • 159.Zhang XC, Strassman AM, Burstein R & Levy D Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J. Pharmacol. Exp. Ther 322, 806–812 (2007). [DOI] [PubMed] [Google Scholar]
  • 160.Rozniecki JJ, Dimitriadou V, Lambracht-Hall M, Pang X & Theoharides TC Morphological and functional demonstration of rat dura mater mast cell–neuron interactions in vitro and in vivo. Brain Res. 849, 1–15 (1999). [DOI] [PubMed] [Google Scholar]
  • 161.Ottosson A & Edvinsson L Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 17, 166–174 (1997). [DOI] [PubMed] [Google Scholar]
  • 162.Bolay H. et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med 8, 136–142 (2002). [DOI] [PubMed] [Google Scholar]
  • 163.Schain AJ, Melo-Carrillo A, Stratton J, Strassman AM & Burstein R CSD-induced arterial dilatation and plasma protein extravasation are unaffected by fremanezumab: implications for CGRP’s role in migraine with aura. J. Neurosci 39, 6001–6011 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 164.Williamson DJ, Hargreaves RJ, Hill RG & Shepheard SL Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat. Cephalalgia 17, 518–524 (1997). [DOI] [PubMed] [Google Scholar]
  • 165.Schain AJ et al. Activation of pial and dural macrophages and dendritic cells by cortical spreading depression. Ann. Neurol 83, 508–521 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 166.Karatas H. et al. Spreading depression triggers headache by activating neuronal Panx1 channels. Science 339, 1092–1095 (2013). [DOI] [PubMed] [Google Scholar]
  • 167.Pelegrin P & Surprenant A Pannexin-1 mediates large pore formation and interleukin-1β release by the ATP-gated P2X7 receptor. EMBO J. 25, 5071–5082 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 168.Chen SP et al. Inhibition of the P2X7–PANX1 complex suppresses spreading depolarization and neuroinflammation. Brain 140, 1643–1656 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 169.Zhao J, Harrison S & Levy D Meningeal P2X7 signaling mediates migraine-related intracranial mechanical hypersensitivity. J. Neurosci 43, 5975–5985 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 170.Sword J, Croom D, Wang PL, Thompson RJ & Kirov SA Neuronal pannexin-1 channels are not molecular routes of water influx during spreading depolarization-induced dendritic beading. J. Cereb. Blood Flow Metab 37, 1626–1633 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 171.Chen PY et al. Neuronal NLRP3 inflammasome mediates spreading depolarization-evoked trigeminovascular activation. Brain 146, 2989–3002 (2023). [DOI] [PubMed] [Google Scholar]
  • 172.Takizawa T. et al. High-mobility group box 1 is an important mediator of microglial activation induced by cortical spreading depression. J. Cereb. Blood Flow Metab 37, 890–901 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 173.Albrecht DS et al. Imaging of neuroinflammation in migraine with aura: a [11C]PBR28 PET/MRI study. Neurology 92, e2038–e2050 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 174.Hadjikhani N. et al. Extra-axial inflammatory signal in parameninges in migraine with visual aura. Ann. Neurol 87, 939–949 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 175.Klass A, Sánchez-Porras R & Santos E Systematic review of the pharmacological agents that have been tested against spreading depolarizations. J. Cereb. Blood Flow Metab 38, 1149–1179 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 176.Ayata C, Jin H, Kudo C, Dalkara T & Moskowitz MA Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol 59, 652–661 (2006). [DOI] [PubMed] [Google Scholar]
  • 177.Hoffmann U, Dilekoz E, Kudo C & Ayata C Oxcarbazepine does not suppress cortical spreading depression. Cephalalgia 31, 537–542 (2011). [DOI] [PubMed] [Google Scholar]
  • 178.Bogdanov VB et al. Migraine preventive drugs differentially affect cortical spreading depression in rat. Neurobiol. Dis 41, 430–435 (2011). [DOI] [PubMed] [Google Scholar]
  • 179.Richter F, Mikulik O, Ebersberger A & Schaible HG Noradrenergic agonists and antagonists influence migration of cortical spreading depression in rat-a possible mechanism of migraine prophylaxis and prevention of postischemic neuronal damage. J. Cereb. Blood Flow Metab 25, 1225–1235 (2005). [DOI] [PubMed] [Google Scholar]
  • 180.Unekawa M, Tomita Y, Toriumi H & Suzuki N Suppressive effect of chronic peroral topiramate on potassium-induced cortical spreading depression in rats. Cephalalgia 32, 518–527 (2012). [DOI] [PubMed] [Google Scholar]
  • 181.Akerman S & Goadsby PJ Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. Neuroreport 16, 1383–1387 (2005). [DOI] [PubMed] [Google Scholar]
  • 182.Silberstein S. et al. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology 70, 548–555 (2008). [DOI] [PubMed] [Google Scholar]
  • 183.Parker PD et al. Non-canonical glutamate signaling in a genetic model of migraine with aura. Neuron 109, 611–628 e618 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 184.Reinhart KM & Shuttleworth CW Ketamine reduces deleterious consequences of spreading depolarizations. Exp. Neurol 305, 121–128 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 185.Vitale M, Tottene A, Zarin Zadeh M, Brennan KC & Pietrobon D Mechanisms of initiation of cortical spreading depression. J. Headache Pain 24, 105 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 186.Chung DY et al. Determinants of optogenetic cortical spreading depolarizations. Cereb. Cortex 29, 1150–1161 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 187.Hertle DN et al. Effect of analgesics and sedatives on the occurrence of spreading depolarizations accompanying acute brain injury. Brain 135, 2390–2398 (2012). [DOI] [PubMed] [Google Scholar]
  • 188.Sanchez-Porras R. et al. The effect of ketamine on optical and electrical characteristics of spreading depolarizations in gyrencephalic swine cortex. Neuropharmacology 84, 52–61 (2014). [DOI] [PubMed] [Google Scholar]
  • 189.Carlson AP, Abbas M, Alunday RL, Qeadan F & Shuttleworth CW Spreading depolarization in acute brain injury inhibited by ketamine: a prospective, randomized, multiple crossover trial. J. Neurosurg 130, 1–7 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 190.Hoydonckx Y, McKechnie T, Peer M, Englesakis M & Kumar P A systematic review of the efficacy of ketamine for craniofacial pain. Can. J. Pain 7, 2210167 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 191.Afridi SK, Giffin NJ, Kaube H & Goadsby PJ A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology 80, 642–647 (2013). [DOI] [PubMed] [Google Scholar]
  • 192.Etchison AR et al. Low-dose ketamine does not improve migraine in the emergency department: a randomized placebo-controlled trial. West. J. Emerg. Med 19, 952–960 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 193.Benish T. et al. The THINK (Treatment of Headache with Intranasal Ketamine) trial: a randomized controlled trial comparing intranasal ketamine with intravenous metoclopramide. J. Emerg. Med 56, 248–257 e241 (2019). [DOI] [PubMed] [Google Scholar]
  • 194.Coste J, Voisin DL, Luccarini P & Dallel R A role for wind-up in trigeminal sensory processing: intensity coding of nociceptive stimuli in the rat. Cephalalgia 28, 631–639 (2008). [DOI] [PubMed] [Google Scholar]
  • 195.Eide PK Wind-up and the NMDA receptor complex from a clinical perspective. Eur. J. Pain 4, 5–15 (2000). [DOI] [PubMed] [Google Scholar]
  • 196.Parsons CG, Stoffler A & Danysz W Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 53, 699–723 (2007). [DOI] [PubMed] [Google Scholar]
  • 197.Peeters M et al. Effects of pan- and subtype-selective N-methyl-d-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine. J. Pharmacol. Exp. Ther 321, 564–572 (2007). [DOI] [PubMed] [Google Scholar]
  • 198.Reinhart KM, Humphrey A, Brennan KC, Carlson AP & Shuttleworth CW Memantine improves recovery after spreading depolarization in brain slices and can be considered for future clinical trials. Neurocrit. Care 35, 135–145 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 199.Noruzzadeh R. et al. Memantine for prophylactic treatment of migraine without aura: a randomized double-blind placebo-controlled study. Headache 56, 95–103 (2016). [DOI] [PubMed] [Google Scholar]
  • 200.Shanmugam S, Karunaikadal K, Varadarajan S & Krishnan M Memantine ameliorates migraine headache. Ann. Indian Acad. Neurol 22, 286–290 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 201.Zhou T, Tang Y & Zhu H Effectiveness and safety of memantine for headache: a meta-analysis of randomized controlled studies. Clin. Neuropharmacol 45, 40–44 (2022). [DOI] [PubMed] [Google Scholar]
  • 202.Peikert A, Wilimzig C & Kohne-Volland R Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 16, 257–263 (1996). [DOI] [PubMed] [Google Scholar]
  • 203.Wang F. et al. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache 43, 601–610 (2003). [DOI] [PubMed] [Google Scholar]
  • 204.van der Hel WS, van den Bergh WM, Nicolay K, Tulleken KA & Dijkhuizen RM Suppression of cortical spreading depressions after magnesium treatment in the rat. Neuroreport 9, 2179–2182 (1998). [DOI] [PubMed] [Google Scholar]
  • 205.Hallak M, Berman RF, Irtenkauf SM, Evans MI & Cotton DB Peripheral magnesium sulfate enters the brain and increases the threshold for hippocampal seizures in rats. Am. J. Obstet. Gynecol 167, 1605–1610 (1992). [DOI] [PubMed] [Google Scholar]
  • 206.Ghabriel MN & Vink R in Magnesium in the Central Nervous System (eds Vink R & Nechifor M) (Univ. Adelaide Press, 2011). [PubMed] [Google Scholar]
  • 207.Bigal ME, Bordini CA, Tepper SJ & Speciali JG Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia 22, 345–353 (2002). [DOI] [PubMed] [Google Scholar]
  • 208.Steiner TJ, Findley LJ & Yuen AW Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 17, 109–112 (1997). [DOI] [PubMed] [Google Scholar]
  • 209.Silberstein S, Goode-Sellers S, Twomey C, Saiers J & Ascher J Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. Cephalalgia 33, 101–111 (2013). [DOI] [PubMed] [Google Scholar]
  • 210.Hoffmann U, Dilekoz E, Kudo C & Ayata C Gabapentin suppresses cortical spreading depression susceptibility. J. Cereb. Blood Flow Metab 30, 1588–1592 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 211.Smith MI et al. Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalalgia 20, 546–553 (2000). [DOI] [PubMed] [Google Scholar]
  • 212.Hauge AW, Asghar MS, Schytz HW, Christensen K & Olesen J Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol. 8, 718–723 (2009). [DOI] [PubMed] [Google Scholar]
  • 213.Tassorelli C. et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology 91, e364–e373 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 214.Martelletti P. et al. Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial. J. Headache Pain 19, 101 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 215.Grazzi L. et al. Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial. J. Headache Pain 19, 98 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 216.Diener HC et al. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia 39, 1475–1487 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 217.Chen SP et al. Vagus nerve stimulation inhibits cortical spreading depression. Pain 157, 797–805 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 218.Liu TT et al. Efficacy profile of noninvasive vagus nerve stimulation on cortical spreading depression susceptibility and the tissue response in a rat model. J. Headache Pain 23, 12 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 219.Morais A. et al. Vagus nerve stimulation inhibits cortical spreading depression exclusively through central mechanisms. Pain 161, 1661–1669 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 220.Andreou AP et al. Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. Brain 139, 2002–2014 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 221.Lloyd JO et al. Cortical mechanisms of single-pulse transcranial magnetic stimulation in migraine. Neurotherapeutics 17, 1973–1987 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 222.Lloyd JO et al. Single-pulse transcranial magnetic stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis. J. Headache Pain 23, 63 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 223.Starling AJ et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia 38, 1038–1048 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 224.Lipton RB et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 9, 373–380 (2010). [DOI] [PubMed] [Google Scholar]
  • 225.Misra UK, Kalita J & Bhoi SK High-rate repetitive transcranial magnetic stimulation in migraine prophylaxis: a randomized, placebo-controlled study. J. Neurol 260, 2793–2801 (2013). [DOI] [PubMed] [Google Scholar]
  • 226.Leahu P. et al. Increased migraine-free intervals with multifocal repetitive transcranial magnetic stimulation. Brain Stimul. 14, 1544–1552 (2021). [DOI] [PubMed] [Google Scholar]
  • 227.Ayata C. Spreading depression: from serendipity to targeted therapy in migraine prophylaxis. Cephalalgia 29, 1095–1114 (2009). [DOI] [PubMed] [Google Scholar]
  • 228.Takizawa T, Ayata C & Chen SP Therapeutic implications of cortical spreading depression models in migraine. Prog. Brain Res 255, 29–67 (2020). [DOI] [PubMed] [Google Scholar]
  • 229.Ayata C. Pearls and pitfalls in experimental models of spreading depression. Cephalalgia 33, 604–613 (2013). [DOI] [PubMed] [Google Scholar]
  • 230.Morais A, Qin T, Ayata C & Harriott AM Inhibition of persistent sodium current reduces spreading depression-evoked allodynia in a mouse model of migraine with aura. Pain 164, 2564–2571 (2023). [DOI] [PubMed] [Google Scholar]
  • 231.Harriott AM, Kaya M & Ayata C Oxytocin shortens spreading depolarization-induced periorbital allodynia. J. Headache Pain 25, 152 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 232.Harriott AM et al. The effect of sex and estrus cycle stage on optogenetic spreading depression induced migraine-like pain phenotypes. J. Headache Pain 24, 85 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 233.Harriott AM, Takizawa T, Chung DY & Chen SP Spreading depression as a preclinical model of migraine. J. Headache Pain 20, 45 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 234.Tuttle AH et al. A deep neural network to assess spontaneous pain from mouse facial expressions. Mol. Pain 14, 1744806918763658 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES